Sunday January 19, 2020

Study Reveals Shorter Duration of Radiation Safe in Treating Prostate Cancer

This method is both safe and effective and could be a viable treatment option for men with low and intermediate-risk of prostate cancer, the study suggested.

0
//
cancer
The study showed that this type of radiation - stereotactic body radiotherapy - is a form of external beam radiation therapy, which reduces the duration of treatment from 45 days to four to five days with no evidence of causing worse toxicity in the long run. Pixabay

Men with low or intermediate-risk prostate cancer can safely undergo higher doses of radiation over a significantly shorter period of time and still have the same, successful outcomes as from a much longer course of treatment, according to researchers including one of Indian-origin.

The study showed that this type of radiation – stereotactic body radiotherapy – is a form of external beam radiation therapy, which reduces the duration of treatment from 45 days to four to five days with no evidence of causing worse toxicity in the long run.

“Most men with low or intermediate-risk prostate cancer undergo conventional radiation, which requires them to come in daily for treatment and takes an average of nine weeks to complete,” said lead author Amar Kishan, Assistant Professor at University of California, Los Angeles, in the US.

smoking
Nearly, 53 per cent men had low-risk disease, 32 per cent had less aggressive intermediate-risk disease and 12 per cent had a more aggressive form of intermediate-risk disease. Pixabay

“With the improvements being made to modern technology, we have found that using stereotactic body radiotherapy, which has a higher dose of radiation, can safely and effectively be done in a much shorter timeframe without additional toxicity or compromising any chance of a cure,” said Kishan.

For the study, the team included 2,142 men with low or intermediate-risk prostate cancer who were treated with stereotactic body radiotherapy. They were followed for a median of 6.9 years.

Nearly, 53 per cent men had low-risk disease, 32 per cent had less aggressive intermediate-risk disease and 12 per cent had a more aggressive form of intermediate-risk disease.

cancer
These are essentially identical to rates following more conventional forms of radiation, which are about 4-5 per cent for low-risk disease and 10 per cent to 15 per cent for intermediate-risk disease. Pixabay

In addition, the recurrence rate for men with low-risk disease was 4.5 per cent, 8.6 per cent for the less aggressive intermediate-risk, and 14.9 per cent for the more aggressive intermediate-risk group, findings published in the journal JAMA Network Open showed.

Overall, the recurrence rate for intermediate-risk disease was 10.2 per cent.

Also Read: Facebook to Come up with ‘Unsend’ Feature on Messenger

These are essentially identical to rates following more conventional forms of radiation, which are about 4-5 per cent for low-risk disease and 10 per cent to 15 per cent for intermediate-risk disease.

This method is both safe and effective and could be a viable treatment option for men with low and intermediate-risk of prostate cancer, the study suggested. (IANS)

Next Story

Most Advanced Radiation Therapy For Cancer Patients Arrives in India

With the most recent introduction of Radixact X9, radiation oncology has reached a new horizon in the race of effective curative treatment for cancer

0
Cancer
Cancer Patients find it more comfortable to be treated under this technology owing to the rotational helical mechanism, also the set-up time is lesser as compared to other therapies. Pixabay

Indraprastha Apollo Hospital in New Delhi on Friday launched the most advanced version of TomoTherapy Radixact X9– the smartest radiation therapy to treat the most complicated cancer tumours.

Tomotherapy comes as a boon for cancer treatment since it has a higher degree of precision, speed and accuracy.

Patients find it more comfortable to be treated under this technology owing to the rotational helical mechanism, also the set-up time is lesser as compared to other therapies.

“The launch of the most advanced version of the Tomotherapy technology is truly a remarkable development in the field of Radiation Oncology. This will be a revolutionary step in the treatment of cancer. With this system we can deliver both fractionated radiotherapy as well as SBRT and Radiosurgery,” said Suneeta Reddy, Managing Director, Apollo Hospitals Group.

“The new generation radiation machine and our highly experienced team enables us to move ahead towards precise and personalised care, therefore improving the quality of life of cancer patients and ensure better clinical outcomes,” Reddy added.

Tomotherapy is effective in treating cancer, irrespective of the stage, especially multiple metastasis. The best outcomes are for treatment of bilateral breast cancer, paediatric oncology and all other forms of cancer.

Cancer
Indraprastha Apollo Hospital in New Delhi on Friday launched the most advanced version of TomoTherapy Radixact X9– the smartest radiation therapy to treat the most complicated cancer tumours. Pixabay

“We are taking precision and excellence to the next level with the revolutionary Radixact-X9: Tomotherapy, system powered by state-of-the-art 3D CT imaging. It uses a linear accelerator to deliver high-dose radiation to the tumour with sub-millimetre precision,” said P ShivaKumar, Managing Director, Indraprastha Apollo Hospitals.

ALSO READ: Four App Startups Sue Social Media Giant Facebook For Anti-Competitive Behaviour

“With the most recent introduction of Radixact X9, radiation oncology has reached a new horizon in the race of effective curative treatment for cancer. Large field size can be targeted at once. 1.35 cms of length can be targeted without repositioning the machine,” ShivaKumar added. (IANS)